9.30

1.53% +0.14

Talis Biomedical Corp (TLIS)

Overview News Price History Financials Discussions Forecast Stock Split

Talis Biomedical Corp stock is currently priced at $9.30, with a 24-hour trading volume of 14,220. It has seen a +1.53% increased in the last 24 hours and a +10.71% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $9.11 pivot point. If it approaches the $9.55 resistance level, significant changes may occur.

Previous Close:

$9.16

Open:

$9.5

24h Volume:

14,220

Market Cap:

$16.94M

Revenue:

$368.00K

Net Income/Loss:

$-75.48M

P/E Ratio:

-0.194

EPS:

-47.9446

Net Cash Flow:

$-56.05M

1W Performance:

+7.89%

1M Performance:

+10.71%

6M Performance:

+49.28%

1Y Performance:

+1,688%

1D Range:

$8.6501

$9.60

52W Range:

$0.432

$9.60

Talis Biomedical Corp Stock (TLIS) Company Profile

Name

Talis Biomedical Corp

Sector

Healthcare (1216)

Industry

Medical Devices (160)

Phone

650 433 3000

Address

230 Constitution Drive, Menlo Park

Employee

242

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

TLIS's Discussions on Twitter

Talis Biomedical Corp Stock (TLIS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-22	Downgrade	BofA Securities	Neutral → Underperform
Sep-27-21	Downgrade	JP Morgan	Neutral → Underweight
Aug-31-21	Downgrade	BTIG Research	Buy → Neutral
Aug-12-21	Downgrade	Piper Sandler	Overweight → Neutral
Aug-11-21	Downgrade	JP Morgan	Overweight → Neutral
Mar-09-21	Initiated	BTIG Research	Buy
Mar-09-21	Initiated	BofA Securities	Neutral
Mar-09-21	Initiated	JP Morgan	Overweight
Mar-09-21	Initiated	Piper Sandler	Overweight

View All

Talis Biomedical Corp Stock (TLIS) Latest News

Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday

Benzinga

Talis Biomedical Corp Stock (TLIS) Financials Data

Talis Biomedical Corp (TLIS) Revenue 2024

TLIS reported a revenue (TTM) of $368.00 thousand for the quarter ending September 30, 2023.

Talis Biomedical Corp (TLIS) Net Income 2024

TLIS net income (TTM) was -$75.48 million for the quarter ending September 30, 2023, a +34.22% increase year-over-year.

Talis Biomedical Corp (TLIS) Cash Flow 2024

TLIS recorded a free cash flow (TTM) of -$56.05 million for the quarter ending September 30, 2023, a +56.84% increase year-over-year.

Talis Biomedical Corp (TLIS) Earnings per Share 2024

TLIS earnings per share (TTM) was -$41.86 for the quarter ending September 30, 2023, a +35.07% growth year-over-year.

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.